Uncategorized

U.S. Patent No. and Title 11,773,600 Wall Paneling System 11,747,306 Pipeline Structural Fault Diagnosis Apparatus and Diagnosis Method 11,704,404 Method for Control-Flow Integrity Protection, Apparatus, Device and Storage Medium 11,624,066 Neurodegenerative Disorders 11,591,865 Method, Device and System of Vibration Reduction Control on Installation of Deepwater Drilling Riser 11,207,326 Accelerated Treatment of COVID-19 and SAR’s Type…

Ann Pokalsky and Patricia Wilczynski Brozek give presentations at AIPLA’s webinar: “Focus on North America: Patent and Trademark Protection in Canada, the U.S. and Mexico.” On April 15, 2020, Ann Pokalsky and Patricia Wilczynski Brozek, presented during AIPLA’s live webinar: “Focus on North America: Patent and Trademark Protection in Canada, the U.S. and Mexico.” They…

AIPLA webinar : “Inequitable Conduct after Regeneron” Ann Pokalsky, a member of AIPLA’s Online Programs Committee, has coordinated a webinar entitled “Inequitable Conduct after Regeneron” to take place Thursday, June 7, 2018, at 12:30-2:00 p.m., ET. The webinar will be presented by Tom Irving, of Finnegan Henderson Farabow Garret & Dunner, LLP and David Hricik,…

U.S. Supreme Court Rules Inter Partes Review Proceedings do not Violate Article III or Seventh Amendment of the Constitution In a much-anticipated decision, the Supreme Court on Tuesday, April 24, 2018, held that inter partes review (IPR) proceedings do not violate Article III or the Seventh Amendment of the Constitution. Oil States Energy Services, LLC v. Greene’s Energy…

CAFC Rules Petitioner has Burden of Proof to Demonstrate Unpatentability of Patent Owner’s Amended Claims in an Inter Partes Review On October 4, 2017, the U.S. Court of Appeals for the Federal Circuit (CAFC) sitting en banc, ruled that the petitioner has the burden of persuasion with respect to demonstrating unpatentability of amended claims proposed by…

Update on Regeneron Pharmaceuticals Inc. v. Merus N.V. On Tuesday, September 12, 2017, as expected, Regeneron Pharmaceuticals Inc. petitioned  the Court of Appeals for the Federal Circuit (CAFC) for a rehearing en banc of its panel decision rendered in Regeneron Pharmaceuticals Inc. v. Merus N.V., 864 F3d 1343, 123 USPQ2d 1469 (Fed. Cir. 2017). On September 26, 2017, Washington…

CAFC Affirms Patent-in-Suit Unenforceable by Drawing an Adverse Inference of Intent to Deceive the USPTO During its Procurement On July 27, 2017, in a panel decision, the Court of Appeals for the Federal Circuit (CAFC) affirmed the district court’s ruling below (Southern District of New York) that Regeneron’s US Patent No. 8,502,018 is unenforceable due…

U.S. Supreme Court Rules Anti-disparagement Clause of Lanham Act Violates Free Speech Clause of the First Amendment On June 19 , 2017, the U.S. Supreme Court in Matal v. Tam, 137 S. Ct. 1744, ruled the anti-disparagement clause under section 2(a) of the Lanham Act violates the Free Speech Clause of the First Amendment and is therefore invalid, affirming…